OLUKOTUN ADEOYE Y 4

What Happened
Olukotun Adeoye Y, a director of Tonix Pharmaceuticals (TNXP), was granted a derivative award covering 22,700 shares on 2026-05-12. The Form 4 reports the acquisition as a grant (code A) of 22,700 shares at $0.00 (total reported value $0). This is an award/option grant — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (appears timely).
• Transaction type: Grant/Award of a derivative security (Code A).
• Amount: 22,700 shares; reported price: $0.00; reported value: $0.
• Vesting: Footnote F1 — the option vests on the earlier of the one‑year anniversary of the grant and the Issuer's 2027 Annual Meeting of Stockholders.
• Shares owned after the transaction: Not disclosed in the provided filing.
• No indication in the provided data of immediate exercise/sale, tax withholding, 10b5-1 plan, or that this is a gift.

Context
This filing documents a compensation-related derivative grant (per the 2026 Stock Incentive Plan) that will vest over time; such grants are common for directors and do not reflect an immediate cash purchase or sale. Until vested and exercised (if these are options), the award does not represent liquid shares available for sale.